Scarica l'app Stockscreener
103.67
1.89%
-2.00
Dopo l'orario di chiusura:
104.49
0.82
+0.79%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Precedente Chiudi:
$105.67
Aprire:
$105.41
Volume 24 ore:
874.04K
Relative Volume:
1.07
Capitalizzazione di mercato:
$5.46B
Reddito:
$338.46M
Utile/perdita netta:
$-310.96M
Rapporto P/E:
-15.88
EPS:
-6.53
Flusso di cassa netto:
$-132.82M
1 W Prestazione:
-6.49%
1M Prestazione:
+0.14%
6M Prestazione:
+6.47%
1 anno Prestazione:
+34.04%
Intervallo 1D:
$103.02
$106.84
Intervallo di 1 settimana:
$103.02
$112.25
Portata 52W:
$64.11
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Nome
Axsome Therapeutics Inc
Settore
Industria
Telefono
(212) 332-3241
Indirizzo
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Confronta AXSM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
103.67 | 5.46B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.16 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.36 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
532.27 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.55 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
219.95 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-07 | Iniziato | Jefferies | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-31 | Reiterato | Mizuho | Outperform |
| 2024-09-03 | Iniziato | Wells Fargo | Overweight |
| 2024-08-06 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-04-29 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2024-01-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-08-08 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Iniziato | Piper Sandler | Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2022-09-07 | Ripresa | Mizuho | Buy |
| 2021-08-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Iniziato | Berenberg | Buy |
| 2021-01-08 | Iniziato | Jefferies | Buy |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-09-29 | Iniziato | BofA Securities | Underperform |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-14 | Iniziato | Cowen | Outperform |
| 2019-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-16 | Reiterato | Guggenheim | Buy |
| 2019-10-16 | Iniziato | Guggenheim | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-28 | Iniziato | SunTrust | Buy |
| 2019-05-23 | Reiterato | H.C. Wainwright | Buy |
| 2019-04-08 | Iniziato | SVB Leerink | Outperform |
| 2019-03-15 | Reiterato | H.C. Wainwright | Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2015-12-15 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis - The Globe and Mail
Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis - The Motley Fool
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm - GlobeNewswire
Is Axsome Therapeutics Stock Worth The Risk? A Comprehensive Analysis - Barchart.com
Fibromyalgia Treatment Market to Reach $3.88 Billion by 2033 | - openPR.com
Axsome in $570 million loan and revolving credit facility with Blackstone - The Pharma Letter
Frontier Capital Management Co. LLC Has $4.47 Million Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Q2 Earnings Estimate for AXSM Issued By Leerink Partnrs - MarketBeat
Transcript : Axsome Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com
William Blair Analysts Boost Earnings Estimates for AXSM - MarketBeat
Cubist Systematic Strategies LLC Invests $9.89 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Fairmount Funds Management LLC Lowers Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Major Depressive Disorder Market Growth to Accelerate - openPR.com
Axsome Therapeutics enters $570M term loan, credit facility with Blackstone - MSN
Axsome’s $570M loan with Blackstone; Altimmune makes its own credit deal - Endpoints News
Axsome Therapeutics Enters $570 Million Credit Deal With Blackstone - marketscreener.com
Axsome Therapeutics (AXSM) Secures $570 Million Credit Facility - GuruFocus
Axsome Enters $570 Mln Term Loan And Revolving Credit Facility With Blackstone - Nasdaq
Axsome Therapeutics Enters $570 Mln Term Loan And Revolving Credit Facility With Blackstone - marketscreener.com
3 Monster Stocks in the Making - aol.com
Axsome secures $570 million credit facility from Blackstone - Investing.com
Axsome secures $570 million credit facility from Blackstone By Investing.com - Investing.com Nigeria
Axsome Therapeutics Secures $570 Million Financing Facility with Blackstone, Retires Previous Loan - Nasdaq
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone - The Manila Times
BNP Paribas Financial Markets Grows Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Raised by Northern Trust Corp - MarketBeat
HC Wainwright Issues Negative Outlook for AXSM Earnings - MarketBeat
Price T Rowe Associates Inc. MD Increases Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
William Blair Has Bullish Forecast for AXSM FY2028 Earnings - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Price Target Lowered to $180.00 at HC Wainwright - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Schonfeld Strategic Advisors LLC - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Given New $162.00 Price Target at Robert W. Baird - MarketBeat
Balyasny Asset Management L.P. Increases Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Trading Up 5.6% Following Better-Than-Expected Earnings - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Releases Earnings Results, Beats Expectations By $0.46 EPS - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Releases Quarterly Earnings Results, Beats Estimates By $0.46 EPS - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Holdings Boosted by Brevan Howard Capital Management LP - MarketBeat
BVF Inc. IL Has $117.44 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
FY2025 EPS Estimates for AXSM Lifted by Cantor Fitzgerald - MarketBeat
Axsome Therapeutics, Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information - ACCESS Newswire
Alethea Capital Management LLC Has $62.13 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Short Interest Down 14.2% in April - MarketBeat
Axsome targets FDA decision on AXS-14 for fibromyalgia in Q2 2025 - MSN
Analysts Are Updating Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Estimates After Its First-Quarter Results - Yahoo Finance
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y - MSN
Axsome Therapeutics Inc Azioni (AXSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):